Merck And Ridgeback’s Molnupiravir, An Investigational Oral Antiviral COVID-19 Treatment, Receives Special Approval For Emergency In Japan

Published by
The Street

By Business Wire Merck (MRK) – Get Merck & Co., Inc. Report, known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics today announced that Japan’s Ministry of Health, Labor and Welfare has granted Special Approval for Emergency in Japan for molnupiravir, an investigational oral antiviral medicine, for infectious disease caused by SARS-CoV-2. Special Approval for Emergency is the process under Article 14-3 of the Pharmaceuticals and Medical Devices Act to approve a medical product swiftly in an emergency situation to protect public health. Under a previously announced su…

Read More

RECENT POST